Cantor Fitzgerald Expects Higher Earnings for Septerna

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Septerna in a research report issued to clients and investors on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($0.14) per share for the year, up from their previous forecast of ($2.01). Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $0.22 million for the quarter.

Separately, Wells Fargo & Company increased their price objective on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Friday, May 16th.

Septerna Price Performance

Shares of NASDAQ SEPN traded down $0.29 on Wednesday, hitting $9.19. The company had a trading volume of 372,784 shares, compared to its average volume of 714,643. The business has a 50 day moving average of $6.73 and a two-hundred day moving average of $13.65. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently bought and sold shares of the company. Woodline Partners LP raised its holdings in shares of Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company's stock worth $3,373,000 after buying an additional 282,585 shares in the last quarter. Checkpoint Capital L.P. acquired a new stake in shares of Septerna in the 1st quarter valued at $4,776,000. BVF Inc. IL raised its position in shares of Septerna by 79.3% during the first quarter. BVF Inc. IL now owns 4,396,124 shares of the company's stock worth $25,454,000 after acquiring an additional 1,944,100 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Septerna during the first quarter valued at $4,174,000. Finally, Driehaus Capital Management LLC increased its position in Septerna by 20.6% in the first quarter. Driehaus Capital Management LLC now owns 3,122,608 shares of the company's stock worth $18,080,000 after purchasing an additional 533,055 shares during the period.

Insider Buying and Selling

In related news, Director Alan Ezekowitz bought 41,355 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were bought at an average cost of $6.00 per share, with a total value of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company's stock, valued at approximately $624,606. This trade represents a 65.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Gil M. Labrucherie bought 6,282 shares of Septerna stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average price of $5.59 per share, with a total value of $35,116.38. Following the acquisition, the chief financial officer now directly owns 36,282 shares of the company's stock, valued at approximately $202,816.38. This represents a 20.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 58,846 shares of company stock worth $352,565 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.